Key Takeaways MRK secures FDA nod for Enflonsia to prevent RSV in infants during or entering their first RSV season. Approval is based on CLEVER study data showing reduced RSV cases and hospitalizations in infants. MRK plans to price Enflonsia at $556 per dose, with orders starting ahead of the 2025-26 RSV season.Merck (MRK) announced FDA approval for its prophylactic long-acting monoclonal antibody, clesrovimab, for the prevention of RSV in newborns and infants born during or entering their first RSV sea ...